|
受注：045-509-1970 |
技術サポート：tech@selleck.co.jp 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
化学情報
|
Synonyms | NSC 241240, JM-8, CBDCA | Storage (From the date of receipt) |
2 years 4°C/3 years -20°C(in the dark) powder |
| 化学式 | C6H12N2O4Pt |
|||
| 分子量 | 371.25 | CAS No. | 41575-94-4 | |
| Solubility (25°C)* | 体外 | Water | Insoluble | |
| Ethanol | Insoluble | |||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
||||
溶剤液（一定の濃度）を調合する
生物活性
| 製品説明 | Carboplatinは、A2780、SKOV-3、IGROV-1、およびHX62細胞において、DNAに結合し、細胞の修復メカニズムを妨害することにより、DNA synthesis阻害剤として作用します。溶液は不安定なので、使用直前に調製してください。DMSOは、プラチナ系薬剤の溶解には推奨されません。薬剤の不活性化を招く可能性があります。 |
|---|---|
| in vitro | Carboplatin exhibits an inhibitory effect on cell proliferation in a human ovarian cancer cell line panel, including A2780, SKOV3, and IGROV-1 cells with IC50 of 6.1 μM, 12.4 μM and 2.2 μM, respectively. This compound also shows the anti-proliferative activities in lung carcinoid cell line, such as UMC-11, H727, and H835 cells with IC50 of 36.4 μM, 3.4 μM and 35.8 μM, respectively. |
| in vivo | In A2780 tumor xenografts, Carboplatin (60 mg/kg via i.p.) given as single agents shows a modest antitumor effect with the relative tumor volumes on day 6 of 8.4 compared to the control of 11.9, and the day 6 tumor weights relative to control (T/C) of 67%. For the VC8 (Brca2-deficient) xenografts, this compound treatment delays tumor growth and reduces tumor mass by 42% compared to the vehicle group. |
| 特徴 | This product is not recommended to be dissolved in dimethylsulfoxide (DMSO). |
プロトコル(参考用のみ)
| 細胞アッセイ | 細胞株 | A2780, SKOV3, IGROV-1 and HX62 |
|---|---|---|
| 濃度 | 0-200 μM | |
| 反応時間 | 72 hours | |
| 実験の流れ | 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assays: Exponentially growing A2780, SKOV3, IGROV-1 and HX62 ovarian cancer cells are plated in 96 well plates. A range of drug concentrations are added and the plates are incubated for 72 hours to allow for 3–4 doubling times. Each experiment is carried out in triplicate. Sulforhodamine B (SRB) assays: Exponentially growing A2780 cells are plated in 96 well microtitre plates. For experiments studying concomitant exposure, cells are exposed to increasing concentrations of both drugs for 96 hours. For experiments studying the effect of sequence of exposure to 17-AAG or this compound cells are exposed to increasing concentrations of 17-AAG or this chemical for 24 hours. A period of 24-hour exposure to the first agent is chosen so that the A2780 cells would be exposed to the first drug for at least one doubling time (18-24 hours). The cells are then washed with sterile phosphate buffered saline and the medium is replenished. Following this, the second drug (to which the cells are not exposed to in the first 24 hours) or medium is added for 96 hours. All experiments are carried out in triplicate. The results of combination studies are analyzed using the well-established principles of median effect analysis method. The effects of the combination are calculated using an in-house spreadsheet. |
|
| 動物実験 | 動物モデル | The A2780 human ovarian cancer cell line is grown as a subcutaneous xenograft in female athymic NCr nude mice (nu/nu) in each flank. |
| 投薬量 | ≤60 mg/kg (When Carboplatin is dissolved in sodium chloride solution, it will induce physio-chemical and pharmacokinetic changes.) | |
| 投与方法 | Administered via i.p. |
参考
|
カスタマーフィードバック
-
Data from [PLoS One, 2012, 8, e72637]
-
Data independently produced by , , Dr. Helen Sadik of Johns Hopkins University
-
Data independently produced by , , Dr. Helen Sadik of Johns Hopkins University
Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：
| Non-canonical dihydrolipoyl transacetylase promotes chemotherapy resistance via mitochondrial tetrahydrofolate signaling [ Nat Commun, 2025, 16(1):8932] | PubMed: 41062483 |
| Screening a living biobank identifies cabazitaxel as a strategy to combat acquired taxol resistance in high-grade serous ovarian cancer [ Cell Rep Med, 2025, 6(6):102160] | PubMed: 40466638 |
| Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1-Aberrant Ovarian and Endometrial Tumors [ Cancer Res, 2025, 10.1158/0008-5472.CAN-24-2360] | PubMed: 39945650 |
| USP9X integrates TGF-β and hypoxia signalings to promote ovarian cancer chemoresistance via HIF-2α-maintained stemness [ Cell Death Dis, 2025, 16(1):312] | PubMed: 40246814 |
| Cancer-metastasis-on-a-chip reveals efficacy of bevacizumab and siRNA in overcoming carboplatin resistance in SKOV3 ovarian cancer within a fibrotic metastatic microenvironment [ Mater Today Bio, 2025, 34:102240] | PubMed: 40917515 |
| Low dose DNA methyltransferase inhibitors potentiate PARP inhibitors in homologous recombination repair deficient tumors [ Breast Cancer Res, 2025, 27(1):8] | PubMed: 39819384 |
| ABCB1 confers resistance to carboplatin by accumulating stem-like cells in the G2/M phase of the cell cycle in p53null ovarian cancer [ Cell Death Discov, 2025, 11(1):132] | PubMed: 40175339 |
| Homologous Repair-Deficient Pancreatic Cancer: Refined Targeting of DNA Damage Response is an Effective Therapeutic Strategy [ United Eur Gastroent, 2025, 13(7):1328-1342] | PubMed: 40823818 |
| NAD+ Boosting Through NRH Supplementation Enhances Treatment Efficacy in EOC In Vitro [ Int J Mol Sci, 2025, 26(4)1719] | PubMed: 40004182 |
| O 6-methylguanine DNA methyltransferase (MGMT) expression in U1242 glioblastoma cells enhances in vitro clonogenicity, tumor implantation in vivo, and sensitivity to alisertib-carboplatin combination treatment [ Front Cell Neurosci, 2025, 19:1552015] | PubMed: 40336841 |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。